A French start-up is currently carrying out a clinical trial in several hospitals. Developed in Nantes by the company Xenothera, XAV-19 helps limit the pulmonary effects of COVID-19.
It may be a miracle drug against Covid-19. The Xav-19 polyclonal antibody is not a vaccine but a curative treatment. The drug was developed in the Xenothera laboratory in Nantes. With the help of XAV-19, it would be possible to avoid resuscitation since its treatment aims to reduce the pain or feeling of persistent tightness in the chest. “When you have a new disease coming up, what is important is to treat people. We treat people with treatments, not with vaccines ” specifies at the microphone of France Televisions, Odile Duvaux, president of the Nantes start-up Xenothera.
This curative treatment is currently in the quantitative phase
For now, the results are very encouraging for Nantes biotech. On the one hand, because this curative treatment is effective against all variants (English, South African and Brazilian) of the coronavirus. On the other hand, clinical trials of XAV-19 are making good progress “We were able to demonstrate in 20 patients that there was no risk and no side effect. Now we are in the quantitative phase where we are going to have 400 patients. We can then measure precisely and statistically the effectiveness of XAV-19 “ explains the president of the Nantes start-up.
“The vaccine is good, but with treatments”
In another interview with France 3 Pays de la Loire, Odile Duveaux insists on the complementarity that a curative treatment could bring to vaccines against Covid-19. “It has been several months since I recall that vaccines are good, but with treatments. We cannot just be vaccinated, because we are targeting people who are not sick but are at risk of becoming so. It is important to protect people who are not sick, but we must also think of people who are already sick, for them it is not a question of vaccine, it is a question of care, we need treatment. , things that heal them ”.
